Optimizing Switch Strategies for Patients With Viral Suppression

In this episode, the first in a yearlong series on Key Decisions in HIV Care, Daniel R. Kuritzkes, MD, and Chloe Orkin, MBChB, FRCP, MD, discuss important considerations when switching ART in patients with viral suppression on their current regimen, including guideline recommendations and data supporting different switch regimen options such as single-tablet triple therapy, 2-drug oral regimens, doravirine-based regimens, and long-acting injectable therapy. Following their dialogue, the faculty field questions from healthcare professionals.Presenters:Daniel R. Kuritzkes, MDChief, Division of Infectious  DiseasesBrigham and Women's HospitalHarriet Ryan Albee Professor of MedicineHarvard Medical SchoolBoston, MassachusettsChloe Orkin, MBChB, FRCP, MDProfessor of HIV  Queen Mary, University of LondonConsultant PhysicianLead for HIV ResearchBarts Health NHS TrustThe Royal London HospitalLondon, United KingdomContent based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.Link to full program:https://bit.ly/2TXTYWx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

There are no comments yet.

Please log in to write the first comment.